New analysis explores how patients and doctors view ritlecitinib for severe hair loss

NCT ID NCT07200128

Completed Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study analyzed data from a database to understand how adults with severe alopecia areata and their doctors experienced treatment with ritlecitinib compared to older treatments. Researchers looked at patient characteristics, treatment history, and doctor satisfaction. The goal was to see how well ritlecitinib works in everyday medical practice.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ritlecitinib
What this could lead to: If successful, this study could help doctors understand how well ritlecitinib works in real-world settings for severe alopecia areata.
What could go wrong: This is a retrospective analysis of existing data, not a controlled trial. It cannot prove cause and effect, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEVERE ALOPECIA AREATA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alopecia areata

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEVERE ALOPECIA AREATA

Contacts and locations

Show contact details

Locations

Pfizer

New York, New York, 10001, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.